Yi Dingwu, Xing Zhenhua
Department of Cardiac Surgery, Extracorporeal Life Support Center of Cardiovascular Surgery, Second Xiangya Hospital, Central South University, Changsha, China.
Department of Emergency Medicine, Second Xiangya Hospital, Central South University, Changsha 410011, China.
Depress Anxiety. 2025 May 5;2025:1885956. doi: 10.1155/da/1885956. eCollection 2025.
Type 2 diabetes mellitus (T2DM) patients with depression are often accompanied by diabetic nephropathy. However, limited prospective studies have investigated the independent association between depression and diabetic nephropathy, as well as its progression among T2DM patients. This study aims to investigate the association between depression and the development or progression of diabetic nephropathy in T2DM patients, utilizing data from the ACCORD Health-Related Quality of Life (HRQL) study. The nine-item Patient Health Questionnaire (PHQ-9) was utilized to assess depressive symptoms at baseline, and at 1, 3, and 4 years. The primary outcomes included deterioration of renal function, macroalbuminuria, and microalbuminuria. The changes in renal function were evaluated using estimated glomerular filtration rate (eGFR). As the severity of depression, measured by the PHQ-9, increased, there was no corresponding rise in the risk of deterioration in renal function (HR, 1.00; 95% CI, 0.98-1.01), macroalbuminuria (HR, 0.99; 95% CI, 0.53-1.86), or microalbuminuria (HR, 1.00; 95% CI, 0.97-1.03) per unit increase in PHQ-9 score. The estimated unadjusted eGFR (mL/min/1.73 m) decline over the entire study period did not significantly differ for each 1-year increase in age (none: 2.21, 95% CI 1.98-2.44; ever depression: 2.51, 95% CI 2.36-2.67; persist depression: 2.28, 95% CI 1.99-2.57; all pairwise -values > 0.05). T2DM patients with depression do not demonstrate lower renal function or an increased rate of renal function decline. Moreover, they do not exhibit a heightened risk of renal function deterioration, macroalbuminuria, or microalbuminuria compared to T2DM patients without depression.
伴有抑郁症的2型糖尿病(T2DM)患者常伴有糖尿病肾病。然而,前瞻性研究较少探讨抑郁症与糖尿病肾病之间的独立关联及其在T2DM患者中的进展情况。本研究旨在利用ACCORD健康相关生活质量(HRQL)研究的数据,探讨抑郁症与T2DM患者糖尿病肾病发生或进展之间的关联。采用9项患者健康问卷(PHQ-9)在基线、第1、3和4年评估抑郁症状。主要结局包括肾功能恶化、大量白蛋白尿和微量白蛋白尿。使用估计肾小球滤过率(eGFR)评估肾功能变化。随着PHQ-9测量的抑郁严重程度增加,肾功能恶化风险(HR,1.00;95%CI,0.98-1.01)、大量白蛋白尿(HR,0.99;95%CI,0.53-1.86)或微量白蛋白尿(HR,1.00;95%CI,0.97-1.03)并未随PHQ-9评分每增加一个单位而相应增加。在整个研究期间,年龄每增加1岁,估计的未调整eGFR(mL/min/1.73 m)下降在无抑郁症组(2.21,95%CI 1.98-2.44)、曾患抑郁症组(2.51,95%CI 2.36-2.67)、持续抑郁症组(2.28,95%CI 1.99-2.57)之间无显著差异(所有两两比较P值>0.05)。伴有抑郁症的T2DM患者并未表现出较低的肾功能或肾功能下降率增加。此外,与无抑郁症的T2DM患者相比,他们并未表现出肾功能恶化、大量白蛋白尿或微量白蛋白尿的风险增加。